Handle With Care: Exicure Inc (NASDAQ: XCUR)

Geode Capital Management LLC recently announced the acquisition of new stake in Exicure Inc (NASDAQ:XCUR). The institutional investor has increased its shareholding in the Healthcare company by 144.85% to 52996.0 shares with purchase of 31352.0 shares. This fresh investment now brings its stake to 0.61% valued currently at $24431.0. In addition, The Vanguard Group, Inc. raised its holdings by 800.0 to 35118.0 shares.

With over 4.36 million Exicure Inc (XCUR) shares trading Tuesday and a closing price of $0.62 on the day, the dollar volume was approximately $2.7 million. The shares have shown a negative half year performance of -44.88% and its price on 01/09/24 gained nearly 10.71%. Currently, there are 4.97M common shares owned by the public and among those 4.13M shares have been available to trade.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Insiders at the company have transacted a total of 3 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 3 occasions, with total insider shares sold totaling 3,400,222 shares.

The top 3 mutual fund holders in Exicure Inc are Fidelity Extended Market Index Fu, Vanguard Extended Market Index Fu, and iShares Core S&P Total US Stock M. Fidelity Extended Market Index Fu owns 43847.0 shares of the company’s stock, all valued at over $20213.0. iShares Core S&P Total US Stock M now owns shares totaling to 0.09% of the shares outstanding.

Shares of Exicure Inc (NASDAQ: XCUR) opened at $0.5794, up $0.02 from a prior closing price of $0.56. The company’s stock has a 5-day price change of 7.60% and -11.49% over the past three months. XCUR shares are trading 6.86% year to date (YTD), with the 12-month market performance down to -59.47% lower. It has a 12-month low price of $0.36 and touched a high of $1.58 over the same period. XCUR has an average intraday trading volume of 561.10K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.27%, 10.03%, and -26.85% respectively.

Institutional ownership of Exicure Inc (NASDAQ: XCUR) shares accounts for 4.33% of the company’s 4.97M shares outstanding. Mutual fund holders own 3.22%, while other institutional holders and individual stakeholders account for 48.80% and 1.12% respectively.

It has a market capitalization of $5.36M and a beta (3y monthly) value of 1.19. The stock’s trailing 12-month PE ratio is 0.48, while the earnings-per-share (ttm) stands at $1.28. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.62% over the week and 15.57% over the month.

Analysts forecast that Exicure Inc (XCUR) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2023. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$8.1 a year ago.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Exicure Inc (XCUR) as a “Hold” at a consensus score of 3.00. Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 1 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the XCUR, a number of firms have released research notes about the stock. Chardan Capital Markets stated their Neutral rating for the stock in a research note on December 13, 2021, with the firm’s price target at $2.25-$0.40.

Most Popular

Related Posts